MECHELEN, BELGIUM: Galapagos NV and Alfasigma S.p.A. today announced that they have signed an agreement to transfer Galapagos’ Jyseleca® (filgotinib) business to Alfasigma, marking a significant milestone in Galapagos’ transformation into an innovative biotechnology company with a best-in-class research and development pipeline aimed at addressing high unmet patient needs in immunology and oncology. The agreement…
All posts tagged Galapagos NV
e-therapeutics collaborates with Galapagos to discover new therapeutic strategies
OXFORD: e-therapeutics plc has entered a collaboration agreement with Galapagos NV to identify new therapeutic approaches to modulate a specific mechanism involved in idiopathic pulmonary fibrosis (IPF) and potentially in other fibrotic indications. e-therapeutics will continue to be free to explore, both internally and with additional partners, all other pathways involved in IPF and fibrosis.…